Ariana Boswell

All articles by Ariana Boswell

• Florbetaben (18F) receives orphan drug designation to diagnose ATTR

  The European Union has granted Orphan Drug Designation to the radioactive tracer florbetaben (18F) for the diagnosis of ATTR-CM.

• Review calls for more research on SGLT2 inhibitor use in ATTR-CM

  While SGLT2i may improve survival and cardiovascular outcomes in ATTR-CM, further research is needed to fully evaluate its clinical utility.

• Study finds new SPECT/CT approach may improve ATTR-CM diagnosis

  A recent study developed a simple mathematical tool that accurately detects cases of ATTR-CM based on SPECT/CT imaging.

• UK approves acoramidis to treat ATTR-CM

  Acoramidis, a transthyretin stabilizer, has been approved for adults living with ATTR-CM in the United Kingdom.

• Age, left atrium size associated with atrial fibrillation in ATTR-CM

  In a recent study, left atrial dilation and advanced age were identified as predictors of atrial fibrillation in patients with ATTR-CM.

• Nex-Z receives Regenerative Medicine Advanced Therapy designation for ATTR-CM

  Nex-z, a CRISPR/Cas9 therapy, was found to promote sustained and prolonged reduction of transthyretin levels in patients with ATTR-CM.

• Biomarkers of worsening ATTR-CM identified in patients on tafamidis

  NT-proBNP levels and oral diuretic use were associated with cardiac disease worsening in patients with ATTR-CM taking tafamidis.

• Gene‑modulating therapies show promise in ATTR-CM

  A recent review article explores a variety of therapies being developed to target the root cause of ATTR-CM.

• FDA approves vutrisiran to treat ATTR-CM

  The FDA has approved vutrisiran (AMVUTTRA®) for the treatment of ATTR-CM based on favorable results from the HELIOS-B clinical trial.

• Webinar: Strategies for supporting mental health with ATTR-CM

  In a recent webinar, Meghan Beier, PhD, MA highlights several strategies for managing the emotional impacts of ATTR-CM.